1020104-60-2

Upstream product

• 170899-08-8 N-(tert-butoxycarbonyl)-D-allylglycine 
• 622-33-3 N-benzyloxyamine 
• 1020104-28-2 (-)-(1-benzyloxycarbamoyl-but-3-(R)-enyl)-carbamic acid tert-butyl ester 
• 1020104-59-9 (+)-{1-[benzyloxy-(2-chloromethyl-allyl)-carbamoyl]-but-3-enyl}-carbamic acid tert-butyl ester 

Downstream Products

• 1020104-61-3 (-)-(1-benzyloxy-6-morpholin-4-ylmethyl-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-carbamic acid tert-butyl ester 
• 1020104-62-4 (-)-N-(1-benzyloxy-6-morpholin-4-ylmethyl-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-4-(4-chloro-phenoxy)-benzenesulfonamide 
• 1020104-58-8 (-)-4-(4-chloro-phenoxy)-N-(1-hydroxy-6-morpholin-4-ylmethyl-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-benzenesulfonamide 

Relevant academic research and scientific papers

Discovery of novel cobactin-t based matrix metalloproteinase inhibitors via a ring closing metathesis strategy

The discovery of potent N-hydroxyl caprolactam matrix metalloproteinase (MMP) inhibitors (6) based on the natural product Cobactin-T (2) is described. The synthetic method, which utilizes the ring closing metathesis reaction, is compatible to provide comp

HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS

This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.